Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway

Autoimmune DiseaseRheumatoid Arthritis

Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis

BioDrugs.

Nakayamada S, Kubo S, Iwata S, Tanaka Y

doi: 10.1007/s40259-016-0190-5

Rheumatoid Arthritis

Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors

Expert Rev Clin Immunol.

Atzeni F, Talotta R, Nucera V, Marino F, Gerratana E, Sangari D, Masala IF, Sarzi-Puttini P

doi: 10.1080/1744666X.

Rheumatoid Arthritis

Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts

J Clin Med.

Mueller RB, Hasler C, Popp F, Mattow F, Durmisi M, Souza A, Hasler P, Rubbert-Roth A, Schulze-Koops H, Kempis JV

doi: 10.3390/jcm8101548.

Rheumatoid Arthritis

Components of treatment delay in rheumatoid arthritis differ according to autoantibody status: validation of a single-centre observation using national audit data

Rheumatology (Oxford).

Pratt AG, Lendrem D, Hargreaves B, Aslam O, Galloway JB, Isaacs JD

doi: 10.1093/rheumatology/kew261

Rheumatoid Arthritis

A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis

Rheumatology (Oxford).

Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope AP, Winthrop KL, Galloway JB

doi: 10.1093/rheumatology/

PsoriasisPsoriatic ArthritisRheumatoid Arthritis

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data

Ann Rheum Dis.

Mease P, Charles-Schoeman C, Cohen S, Fallon L, Woolcott J, Yun H, Kremer J, Greenberg J, Malley W, Onofrei A, Kanik KS, Graham D, Wang C, Connell C, Valdez H, Hauben M, Hung E, Madsen A, Jones TV, Curtis JR

doi: 10.1136/annrheumdis-2019-216761.

Psoriatic ArthritisRheumatoid Arthritis

Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis

Patient Prefer Adherence.

Svedbom A, Storck C, Kachroo S, Govoni M, Khalifa A

doi: 10.2147/PPA.S128665.

Rheumatoid Arthritis

Glucocorticoid-trials in rheumatoid arthritis mostly study representative real-world patients: A systematic review and meta-analysis

Semin Arthritis Rheum.

Palmowski A, Nielsen SM, Buttgereit T, Palmowski Y, Boers M, Christensen R, Buttgereit F

doi: 10.1016/j.semarthrit.2020.02.016.

Rheumatoid Arthritis

Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Ann Rheum Dis.

Rutherford AI, Subesinghe S, Hyrich KL, Galloway JB

doi: 10.1136/annrheumdis-

Related content

Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis

Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors

Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts

Components of treatment delay in rheumatoid arthritis differ according to autoantibody status: validation of a single-centre observation using national audit data

A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data

Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis

Glucocorticoid-trials in rheumatoid arthritis mostly study representative real-world patients: A systematic review and meta-analysis

Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis